Conference Track

Multiple Myeloma

Source: CCO Independent Conference Coverage of the American Society of Hematology 2007 Annual Meeting*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Capsule Summaries

High ORR in Newly Diagnosed Multiple Myeloma With Bortezomib/Lenalidomide/Dexamethasone Combination
Thalidomide/Dexamethasone More Active and More Toxic Than Melphalan/Prednisone in Elderly Patients With Treatment-Naive Multiple Myeloma
Molecular Remissions Attained With Consolidation Bortezomib/Thalidomide/Dexamethasone Therapy in Patients With MM Responding to Autografting
Bortezomib/Melphalan/Prednisone Superior to Melphalan/Prednisone in Patients With Previously Untreated Multiple Myeloma
Lenalidomide Plus High-Dose Dexamethasone Superior to High-Dose Dexamethasone in the Treatment of Newly Diagnosed Multiple Myeloma
Bortezomib/Thalidomide/Dexamethasone Superior to Thalidomide/Dexamethasone for Induction Therapy in Newly Diagnosed Multiple Myeloma
Superior Survival With Lenalidomide Plus Low-Dose Dexamethasone vs Lenalidomide Plus High-Dose Dexamethasone in Newly Diagnosed Multiple Myeloma
Improved Progression-Free and Overall Survival With Melphalan, Prednisone, and Thalidomide Compared With Melphalan and Prednisone in Elderly Patients With Newly Diagnosed Multiple Myeloma
5-Day Course of Novel Proteasome Inhibitor Carfilzomib (PR-171) Results in Strong, Sustained Proteasome Inhibition
Novel Proteasome Inhibitor Carfilzomib Given Twice Weekly on Consecutive Days Active Well Tolerated in Patients With Hematologic Malignancies
Plerixafor Enhances CD34+ Mobilization in Patients With Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation

Expert Analysis

Multiple Myeloma

Program Director:
Roy A. Beveridge, MD

Faculty:
Kenneth Anderson, MD Sagar Lonial, MD Robert Z. Orlowski, MD, PhD

Moderator:
Seema Singhal, MD

Learning Objectives

Upon completion of this activity, participants should be able to:

Describe the use of the novel agents thalidomide, lenalidomide, and bortezomib in first-line treatment of patients eligible for stem cell transplantation
Review the efficacy of adding novel agents to melphalan/prednisone combinations in patients ineligible for stem cell transplantation
Summarize how various combination therapies affect stem cell mobilization
Explain the relevance of molecular remission to disease response assessment
Discuss the potential role of new agents in the treatment of relapsed or refractory multiple myeloma

CME CREDIT INFORMATION

Release Date: 02/21/08

Expiration Date: 02/20/09

Physicians: maximum of 1.25 AMA PRA Category 1 Credit(s)™

Pharmacists: 1.4 contact hours (0.14 CEUs)

Registered Nurses: 1.4 Nursing CE credits

Status: Please log in to view status

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.